News

   

Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD

Top-line Data Expected in the Third Quarter of 2022 LONDON and…

Destiny Pharma Lancet Report

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Important…

Amber Implants Closes US$10 M Series A Financing

The Hague, Netherlands, 19 January 2022: Amber Implants, an…

Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval for Emcitate® in the US

Emcitate® (tiratricol) is the first potential treatment of…

Destiny Pharma Strategy/Company/Ops Update

Brighton, United Kingdom, 17 January 2022 – Destiny Pharma…

Novo Seeds Provides Business Update on a Record Year – Building Exceptional Companies for Global Impact

Over US$ 550 million raised by portfolio companies in 2021 …

BioInnovation Institute Awarded Grant to Launch a New Initiative Focused on Women’s Health

COPENHAGEN, Denmark, 11 January 2022 – BioInnovation Institute…

Future Fertility Raises Series A to Progress First-In-Class AI-Enabled Fertility Solutions to Improve IVF Outcomes

First company to develop an AI product to predict egg viability…

Novo Holdings – Grant of DKK 200 million will create better future prospects for young Syrian refugees in Jordan

Youth unemployment in Jordan is record high, and up to 50% of…

Versameb to Attend Biotech Showcase 2022

Versameb AG (“Versameb”), a pre-clinical stage company focused…

Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset

ENHANCE-2 Screening Complete with Full Enrollment Expected in…

Genmab and Synaffix Enter into License Agreement for ADC Technology

Synaffix to provide access to proprietary antibody-drug conjugate…

Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference

LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona…

Novo Holdings participates in EUR 110 million first closing of Sound Bioventures Fund I

Copenhagen, Denmark – Novo Holdings, a leading international…

Novo Holdings to acquire Ritedose

Novo Holdings A/S (“Novo Holdings”) today announced that…

AMSilk Partners with Mercedes-Benz to Present a Sustainable Bio-Based Product

The use of a biotechnology-based and certified-vegan…

EXACT Therapeutics AS Announces Allowance of Patent Application in Europe for Acoustic Cluster Therapy (ACT®)

OSLO/LONDON, 22 December 2021: Christmas came early at EXACT…

Novo Holdings invests EUR 86 million in 21st.BIO, a new bioindustrial scale-up company building on technology base from Novozymes

COPENHAGEN, DENMARK — Novo Holdings, a leading international…

EXACT Therapeutics AS Awarded NOK 7.4 M Grant for the Development of its Next Generation Ultrasound Transducer and Navigation System for ACT®

OSLO/ LONDON: 21 December 2021: EXACT Therapeutics AS (“EXACT-Tx”…

Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline

Chord Therapeutics was launched by Omega Funds in October…

We’d love to hear from you.

For more information about Optimum Strategic Communications, please get in touch.

Get in touch
© Optimum Strategic Communications.